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G rowth stimulation expressed gene 2 (ST2) is a transmembrane protein and a member of the Toll-interleukin 1 receptor superfamily (1,2). ST2 binds interleukin-33 in response to cardiac disease or injury and elicits a cardioprotective effect by mitigating the maladaptive responses of the myocardium to overload states (3, 4) . A truncated soluble form of ST2 (soluble ST2 [sST2]) competes with the membrane-bound form in this interleukin -33 binding. Elevated levels of sST2 signal the presence and severity of adverse cardiac remodeling and tissue fibrosis, which may occur in response to an acute coronary syndrome event or worsening heart failure (HF) (3,5). Higher levels of sST2 are associated with more severe clinical symptoms and with other objective measures of HF severity, such as higher C-reactive protein, higher natriuretic peptide levels, lower left ventricular ejection fraction, and higher diastolic filling pressures (6-12). Elevated circulating sST2 levels have been associated with an increased risk for mortality and sudden cardiac death in outpatients with HF (9,13-15), as well as in acute HF (16).
However, most studies have only measured sST2 at a single timepoint (predominantly at baseline) and only described the relationship with long-term all-cause mortality.
In this post-hoc study utilizing blood specimens collected serially in the ASCEND-HF (Acute Study of Clinical Effectiveness of Nesiritide in Decompensated Heart Failure) trial, we examined the relationship between baseline and serial levels of sST2 and dyspnea status, hospitalization (at 30 days), and death (at 180 days). We also examined the effect of nesiritide therapy on sST2 levels, hypothesizing that the vasodilatory effects of nesiritide may relieve volume overload more effectively than a placebo, thereby potentially achieving greater reduction in sST2 levels. and a coefficient of variation <5%; the limit of detection is at 1.8 ng/ml, and the limit of quantifica- Table 4 ). Specifically, there was a positive association between baseline sST2 and outcomes for high (above median) baseline NT-proBNP, and a negative association between sST2 and outcomes for the 180-day mortality risk for baseline sST2 levels ( Figure 2A) . Table 2) . Elevated follow-up sST2 was also associated with increased risk of death/worsening HF before discharge (OR: 2.41; 95% CI: 1.25 to 4.63; p 0.008).
METHODS
After adjustments for the ASCEND-HF risk model, the prognostic significance of follow-up sST2 levels was only relevant for 180-day death, and remained borderline significant with the addition of baseline NT-proBNP to the ASCEND-HF risk model (adjusted HR: 1.61; 95% CI: 1.00 to 2.60; p 0.051) ( Table 2) . Table 3C ). Figure 4) . (Table 3) . (Table 4) . Additionally, sST2 levels at 30-day follow-up and absolute changes in sST2 levels from baseline to 30 days were similar between the 2 treatment groups ( Table 4) .
DISCUSSION
There are 4 major findings from this study. First, we observed that baseline sST2 levels elevated in the acute HF setting were comparable with earlier reports (23-26), and were higher than those reported in the chronic setting (cutoff at 35 ng/ml) (9,15).
Second, the prognostic findings for sST2 at baseline for 180-day outcomes were generally neutral after adjustments for the ASCEND-HF risk model and 
